VaxNewMO
SAINT LOUIS, United States · Founded 2017 · $6.6M raised
- Headquarters
- SAINT LOUIS, Missouri
- Employees
- 1–10
- Founded
- 2017
- Business Model
- B2G
- Total Funding
- $6.6M
- Last Round
- $3.0M GrantSep 2023
- Rounds
- 3
About
VaxNewMo is a St. Louis-based bioscience startup developing next-generation conjugate vaccines against infectious diseases, with a lead program targeting pneumococcus — a leading cause of pneumonia, meningitis, and bloodstream infections. The company's proprietary bioconjugation technology uses conjugating enzymes within E. coli to produce vaccines without traditional synthetic chemistry, supported by NIH SBIR Phase II funding.
Summary
VaxNewMO is a Biotech company based in SAINT LOUIS, United States, founded in 2017. It has raised $6.6M in total across 3 rounds, most recently a $3.0M Grant round in Sep 2023. Investors include National Institutes of Health, Arch Grants and BioGenerator Ventures.
Funding History
Sep 2023
Sign up to see all 3 rounds
Grant — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/vaxnewmo"><img src="https://indexed.vc/api/badge/company/vaxnewmo" alt="VaxNewMO on Indexed.vc" width="260" height="76" /></a>